CAMP4 Therapeutics Corp
Veridion Score
Composite trend over time
Why is CAMP moving today?
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CAMP.
CAMP insider activity
CAMP4 Therapeutics Corp
No multi-insider buying cluster in the last 90 days
Net buying: $13.1M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-15 | 2025-09-11 | PARMAR KUSH | Insider | buy | $1.53 | 2,941,176 | 2,941,176 | $4.5M | SEC Form 4 |
| 2025-09-15 | 2025-09-11 | Schwab Andrew J. | Insider | buy | $1.53 | 2,941,176 | 2,941,176 | $4.5M | SEC Form 4 |
| 2025-09-11 | 2025-09-11 | Gold Kelly | Insider | buy | $1.65 | 6,060 | 67,877 | $10K | SEC Form 4 |
| 2025-09-11 | 2025-09-11 | Mandel-Brehm Josh | Insider | buy | $1.65 | 6,060 | 278,417 | $10K | SEC Form 4 |
| 2025-09-11 | 2025-09-11 | Maricich Yuri | Insider | buy | $1.65 | 6,060 | 6,060 | $10K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 5 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCAMP contract awards, year to date.
Public federal awards linked to this ticker.
CAMP lobbying filings, year to date.
Registered lobbying filings matched to CAMP4 Therapeutics Corp.